Lquin: Advanced Fluoroquinolone Therapy for Severe Bacterial Infections
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.46 | $41.28 (0%) | 🛒 Add to cart |
| 120 | $0.42 | $55.04 $49.88 (9%) | 🛒 Add to cart |
| 180 | $0.37 | $82.56 $66.22 (20%) | 🛒 Add to cart |
| 270 | $0.27 | $123.84 $73.96 (40%) | 🛒 Add to cart |
| 360 | $0.25
Best per pill | $165.12 $89.44 (46%) | 🛒 Add to cart |
Lquin (levofloxacin) is a broad-spectrum fluoroquinolone antibiotic designed for the targeted treatment of complicated and resistant bacterial infections. With its potent bactericidal activity and excellent tissue penetration, Lquin offers clinicians a reliable option for managing severe community-acquired and nosocomial infections where first-line therapies have failed or are contraindicated. Its once-daily dosing regimen supports patient compliance while maintaining therapeutic drug levels throughout the treatment period. The medication demonstrates particular efficacy against Gram-negative pathogens, including Pseudomonas aeruginosa, while maintaining activity against many Gram-positive and atypical organisms.
Features
- Active ingredient: Levofloxacin 250mg, 500mg, or 750mg film-coated tablets
- Pharmacological class: Third-generation fluoroquinolone antibiotic
- Mechanism: Inhibition of bacterial DNA gyrase and topoisomerase IV enzymes
- Bioavailability: Approximately 99% with oral administration
- Half-life: 6-8 hours in patients with normal renal function
- Protein binding: 24-38%
- Excretion: Primarily renal as unchanged drug
- Special formulation: Optimized for consistent absorption with or without food
Benefits
- Provides rapid bactericidal action against a wide spectrum of pathogenic bacteria
- Offers convenient once-daily dosing that supports treatment adherence
- Demonstrates excellent penetration into lung tissue, prostate, and other difficult-to-treat sites
- Effective against many multidrug-resistant organisms, including some MRSA strains
- Suitable for sequential therapy (IV to oral conversion) to facilitate early discharge
- Maintains activity in both aerobic and anaerobic environments
Common use
Lquin is indicated for the treatment of adults with infections caused by susceptible strains of designated microorganisms. Primary indications include community-acquired pneumonia of mild to moderate severity, complicated urinary tract infections including pyelonephritis, acute bacterial exacerbation of chronic bronchitis, acute bacterial sinusitis, uncomplicated skin and skin structure infections, and chronic bacterial prostatitis. It is also used for inhalational anthrax post-exposure prophylaxis and plague. The medication is particularly valuable in cases where penicillin or other beta-lactam antibiotics are contraindicated due to allergy or resistance patterns.
Dosage and direction
The recommended dosage and duration of Lquin therapy varies according to the type and severity of infection, as well as renal function. For most infections in patients with creatinine clearance >50 mL/min, the usual dose is 500 mg once daily for 7-14 days. For complicated urinary tract infections or acute pyelonephritis, 750 mg once daily for 5 days may be prescribed. For community-acquired pneumonia, 500 mg once daily for 7-14 days is standard. Tablets should be swallowed whole with a full glass of water, and may be taken without regard to meals, though consistency in administration relative to food is recommended. Patients should maintain adequate hydration during treatment. Dosage adjustment is necessary in renal impairment according to specific creatinine clearance calculations.
Precautions
Patients should be advised that Lquin may cause dizziness and lightheadedness; therefore, caution should be exercised when driving or operating machinery. Tendon inflammation or rupture may occur during or after therapy, particularly in elderly patients and those receiving concomitant corticosteroid therapy. Patients should discontinue Lquin and avoid exercise if pain, inflammation, or tendon rupture occurs. Photosensitivity reactions may occur; patients should avoid excessive sunlight and artificial UV light and use protective measures. Blood glucose disturbances may occur, particularly in diabetic patients; monitoring is recommended. Lquin may prolong the QT interval in some patients; use with caution in those with known QT prolongation, uncorrected hypokalemia, or concurrent use of other QT-prolonging drugs.
Contraindications
Lquin is contraindicated in patients with known hypersensitivity to levofloxacin, other quinolone antibiotics, or any component of the formulation. It should not be used in patients with a history of tendon disorders related to fluoroquinolone use. The medication is contraindicated in patients with known QT prolongation, those taking Class IA or III antiarrhythmic agents, and those with uncorrected hypokalemia. Use is contraindicated in pediatric patients, adolescents, and pregnant women due to risk of arthropathy. Patients with myasthenia gravis should not receive Lquin due to potential exacerbation of muscle weakness.
Possible side effect
The most commonly reported adverse reactions include nausea (3-7%), diarrhea (1-5%), headache (1-6%), constipation (1-3%), dizziness (1-3%), and insomnia (1-4%). Less frequent but more serious adverse effects may include tendonitis or tendon rupture, peripheral neuropathy, central nervous system effects (seizures, anxiety, confusion), QT interval prolongation, hypoglycemia or hyperglycemia, photosensitivity, hepatotoxicity, and Clostridium difficile-associated diarrhea. Hematologic abnormalities including leukopenia and eosinophilia may occur. Psychiatric reactions including depression and suicidal thoughts have been reported rarely.
Drug interaction
Lquin may interact with several classes of medications. Antacids containing magnesium or aluminum, sucralfate, metal cations such as iron, and multivitamins containing zinc may significantly reduce absorption; administer at least 2 hours before or 6 hours after Lquin. Nonsteroidal anti-inflammatory drugs may increase the risk of CNS stimulation and seizures. Warfarin therapy requires close monitoring of prothrombin time due to potential enhancement of anticoagulant effect. Diabetic medications may require adjustment due to potential hypoglycemic or hyperglycemic effects. QT-prolonging drugs (antiarrhythmics, antipsychotics, antidepressants, macrolides) may have additive effects on cardiac repolarization. Probenecid may decrease renal clearance of levofloxacin.
Missed dose
If a dose of Lquin is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Maintaining consistent blood levels is important for efficacy, so patients should be counseled on adherence strategies. If multiple doses are missed, patients should contact their healthcare provider for guidance on whether to extend the treatment duration.
Overdose
In case of overdose, symptomatic and supportive care should be instituted. ECG monitoring is recommended due to potential QT prolongation. Hemodialysis removes approximately 14% of the administered dose over 4 hours and may be considered in severe cases. Symptoms of overdose may include dizziness, tremor, nausea, vomiting, decreased consciousness, and seizures. Management should include gastric lavage if presentation is early after ingestion. Maintenance of adequate hydration and monitoring of renal function is important. There is no specific antidote for levofloxacin overdose.
Storage
Lquin tablets should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be kept in the original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lquin is a prescription medication that should only be used under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for complete information regarding indications, dosage, warnings, and precautions. Individual patient response may vary, and therapeutic decisions should be based on the professional judgment of the treating clinician considering the individual patient’s condition. The manufacturer’s complete prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies demonstrate Lquin’s efficacy with success rates of 85-95% across various indications when used appropriately. In a multicenter trial of community-acquired pneumonia, clinical success was achieved in 92% of patients receiving 500 mg daily for 7-10 days. For complicated urinary tract infections, microbiological eradication rates exceeded 90% with the 750 mg daily regimen. Physicians report satisfaction with Lquin’s predictable pharmacokinetics and reliable coverage of common pathogens. Some clinicians note the importance of appropriate patient selection given the black box warnings associated with fluoroquinolones. Patient reviews frequently mention the convenience of once-daily dosing but occasionally report gastrointestinal side effects that typically resolve after completion of therapy.